[In vitro susceptibilities of causative organisms isolated from patients with primary respiratory tract infections to BRL 25000 (clavulanic acid/amoxicillin)]. 1985

K Deguchi, and S Fukayama, and Y Nishimura, and N Yokota, and S Tanaka, and S Oda, and Y Matsumoto, and R Ikegami, and K Sato, and T Fukumoto

The in vitro susceptibilities of various causative organisms recently isolated from patients with primary respiratory tract infections to BRL 25000 (a formulation of amoxicillin, 2 parts, and potassium clavulanate, 1 part), amoxicillin (AMPC), cefaclor (CCL), cephalexin (CEX), cefadroxil (CDX) and cefroxadine (CXD) were determined. beta-Lactamase producing strains were detected by nitrocefin chromogenic method and PCG acidometric method. The frequency of isolation of beta-lactamase production in strains of S. aureus, H. influenzae, B. catarrhalis and K. pneumoniae was 92%, 18%, 36% and 98%, respectively. Against S. aureus strains with MIC values to AMPC of less than or equal to 100 micrograms/ml and CEX of less than or equal to 25 micrograms/ml BRL 25000 showed MIC values in the range 0.39-6.25 micrograms/ml with inocula of 10(6) CFU/ml, while BRL 25000 required 12.5-100 micrograms/ml of concentrations for inhibition of the strains with MIC values to AMPC of greater than 100 micrograms/ml and CEX of greater than or equal to 25 micrograms/ml. Against S. pyogenes and S. pneumoniae BRL 25000 showed MIC values in the range less than 0.024-0.10 micrograms/ml with inocula of 10(6) CFU/ml, which is much more active than CCL, CEX, CDX and CXD and slight less active than AMPC. Against H. influenzae and B. catarrhalis BRL 25000 showed MIC values in the range 0.20-6.25 micrograms/ml with inocula of 10(6) CFU/ml, which showed most potent activity among the agents tested. The activity of BRL 25000 against K. pneumoniae was approximately equal to that of CCL and superior to that of AMPC, CEX, CDX and CXD.

UI MeSH Term Description Entries
D012141 Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases. Respiratory System Infections,Upper Respiratory Tract Infection,Upper Respiratory Tract Infections,Infections, Respiratory,Infections, Respiratory Tract,Infections, Upper Respiratory,Infections, Upper Respiratory Tract,Respiratory Infections,Upper Respiratory Infections,Infection, Respiratory System,Infection, Respiratory Tract,Respiratory Infection, Upper,Respiratory System Infection,Respiratory Tract Infection
D002433 Cefaclor Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN. 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, (6R-(6alpha,7beta(R*)))-,Ceclor,Cefaclor Anhydrous,Cefaclor Monohydrate,Keclor,Lilly 99638,S-6472,S 6472,S6472
D002434 Cefadroxil Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative. 4-Hydroxycephalexin,5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))-,BL-S 578,BL-S578,Bidocef,Cefadroxil Anhydrous,Cefadroxil Monohydrate,Cephadroxyl,Duricef,S-578,S578,Ultracef,4 Hydroxycephalexin,BL S 578,BL S578,BLS 578,BLS578,S 578
D002506 Cephalexin A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms. 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))-,Cefalexin,Cephalexin Dihydride,Cephalexin Hemihydrate,Cephalexin Hydrochloride,Cephalexin Monohydrate,Cephalexin Monohydrochloride,Cephalexin Monohydrochloride, Monohydrate,Cephalexin, (6R-(6alpha,7alpha(R*)))-Isomer,Cephalexin, (6R-(6alpha,7beta(S*)))-Isomer,Cephalexin, (6R-(6alpha,7beta))-Isomer,Cephalexin, Monosodium Salt,Cephalexin, Monosodium Salt, (6R-(6alpha,7beta))-Isomer,Ceporexine,Palitrex
D002515 Cephradine A semi-synthetic cephalosporin antibiotic. Anspor,Cefradine,Cephradine Dihydrate,Cephradine, Non-Stoichiometric Hydrate,Dexef,Kelsef,Maxisporin,Nicef,SQ-11436,Sefril,Septacef,Velocef,Velosef,Zeefra Gé,Cephradine, Non Stoichiometric Hydrate,Dihydrate, Cephradine,Non-Stoichiometric Hydrate Cephradine,SQ 11436,SQ11436
D002969 Clavulanic Acids Acids, salts, and derivatives of clavulanic acid (C8H9O5N). They consist of those beta-lactam compounds that differ from penicillin in having the sulfur of the thiazolidine ring replaced by an oxygen. They have limited antibacterial action, but block bacterial beta-lactamase irreversibly, so that similar antibiotics are not broken down by the bacterial enzymes and therefore can exert their antibacterial effects. Acids, Clavulanic
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000658 Amoxicillin A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration. Hydroxyampicillin,Actimoxi,Amoxicillin Anhydrous,Amoxicillin Monopotassium Salt,Amoxicillin Monosodium Salt,Amoxicillin Sodium,Amoxicillin Trihydrate,Amoxicillin, (R*)-Isomer,Amoxicilline,Amoxil,Amoxycillin,BRL-2333,Clamoxyl,Clamoxyl G.A.,Clamoxyl Parenteral,Penamox,Polymox,Trimox,Wymox,BRL 2333,BRL2333

Related Publications

K Deguchi, and S Fukayama, and Y Nishimura, and N Yokota, and S Tanaka, and S Oda, and Y Matsumoto, and R Ikegami, and K Sato, and T Fukumoto
February 1985, The Japanese journal of antibiotics,
K Deguchi, and S Fukayama, and Y Nishimura, and N Yokota, and S Tanaka, and S Oda, and Y Matsumoto, and R Ikegami, and K Sato, and T Fukumoto
February 1985, The Japanese journal of antibiotics,
K Deguchi, and S Fukayama, and Y Nishimura, and N Yokota, and S Tanaka, and S Oda, and Y Matsumoto, and R Ikegami, and K Sato, and T Fukumoto
August 1985, The Japanese journal of antibiotics,
K Deguchi, and S Fukayama, and Y Nishimura, and N Yokota, and S Tanaka, and S Oda, and Y Matsumoto, and R Ikegami, and K Sato, and T Fukumoto
February 1985, The Japanese journal of antibiotics,
K Deguchi, and S Fukayama, and Y Nishimura, and N Yokota, and S Tanaka, and S Oda, and Y Matsumoto, and R Ikegami, and K Sato, and T Fukumoto
February 1985, The Japanese journal of antibiotics,
K Deguchi, and S Fukayama, and Y Nishimura, and N Yokota, and S Tanaka, and S Oda, and Y Matsumoto, and R Ikegami, and K Sato, and T Fukumoto
February 1985, The Japanese journal of antibiotics,
K Deguchi, and S Fukayama, and Y Nishimura, and N Yokota, and S Tanaka, and S Oda, and Y Matsumoto, and R Ikegami, and K Sato, and T Fukumoto
March 1983, The Japanese journal of antibiotics,
K Deguchi, and S Fukayama, and Y Nishimura, and N Yokota, and S Tanaka, and S Oda, and Y Matsumoto, and R Ikegami, and K Sato, and T Fukumoto
March 1983, The Japanese journal of antibiotics,
K Deguchi, and S Fukayama, and Y Nishimura, and N Yokota, and S Tanaka, and S Oda, and Y Matsumoto, and R Ikegami, and K Sato, and T Fukumoto
February 1985, The Japanese journal of antibiotics,
K Deguchi, and S Fukayama, and Y Nishimura, and N Yokota, and S Tanaka, and S Oda, and Y Matsumoto, and R Ikegami, and K Sato, and T Fukumoto
February 1985, The Japanese journal of antibiotics,
Copied contents to your clipboard!